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Abstract
Background: Despite preclinical evidence suggesting a synergistic interaction between ketamine and opioids
promoting analgesia, several clinical trials have not identified dosing regimens capable of eliciting a benefit in the
co-administration of ketamine with opioids.
Methods: Ten healthy volunteers participated in a double blinded, randomised, placebo controlled, crossover
laboratory study in order to determine whether a low dose of ketamine potentiated the antinociceptive effect of
fentanyl without causing an increase in sedative effects. A battery of tests was used to assess both nociception
and sedation including electrical current, pressure, thermal stimuli, psychometric tests, and both subjective and
objective scores of sedation. Target controlled infusions of the study drugs were used. Ketamine and fentanyl
were administered alone and in combination in a double-blinded randomised crossover design. Saline was used
as the control, and propofol was used to validate the tests of sedation. Cardiovascular and respiratory parameters
were also assessed.
Results: The electrical current pain threshold dose response curve of fentanyl combined with ketamine was
markedly steeper than the dose response curve of fentanyl alone. While a ketamine serum concentration of 30
ng/ml did not result in a change in electrical pain threshold when administered alone, when it was added to
fentanyl, the combination resulted in greater increase in pain threshold than that of fentanyl administered alone.
When nociception was assessed using heat and pressure stimuli, ketamine did not potentiate the anti-nociceptive
effect of fentanyl. There was no difference between the sedative effect of fentanyl and fentanyl in combination
with ketamine as assessed by both subjective and objective measures of sedation. Cardiovascular and respiratory
parameters were unaffected by the study drugs at the doses given.
Conclusion:  A serum concentration of ketamine that did not alter indices of sedation potentiated the
antinociceptive effect of fentanyl. This potentiation of antinociception occurred without an increase in sedation
suggesting that low steady doses of ketamine (30–120 ng/ml) might be combined with µ opioid agonists to
improve their analgesic effect in a clinical setting. (296 words)
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Background
Ketamine was patented in 1966 [1], and has long been
known to be associated with short-term analgesia [2].
Considerable interest was renewed in ketamine with the
discovery that it could block the NMDA receptor and
therefore it has a potential role in the management of win-
dup and prevention of subsequent spinal cord sensitisa-
tion. To date, clinical trials that have investigated its use as
an analgesic drug have often described its adverse effects.
This has led some authors to question its use in the man-
agement of postoperative pain [3].
Several animal studies have suggested that the mecha-
nisms for a synergistic interaction between ketamine and
opioids might exist [4] and [5,6]. that combinations of
opioids and NMDA receptor antagonists might result in
an enhanced effect [7] – as might be predicted by the dif-
ferent mechanisms of action of these classes of drugs
[8,9].
The current investigation explored the interaction
between ketamine and the opioid fentanyl in the anticipa-
tion that a low dose of ketamine might potentiate the
analgesic effect of fentanyl. Furthermore, it was hypothe-
sised that the interaction of these drugs might be associ-
ated with selective potentiation of analgesia without
associated increased sedation; that is that potentiation
might occur in the context of a very low dose of ketamine
that was not otherwise associated with brain effects such
as sedation. It was hoped that the identification of such
doses of ketamine may enable better future management
of both opioid sensitive physiological pain and NMDA
receptor mediated sensitisation without the disadvantage
of increased sedation.
Methods
This study was conducted using a double blinded, ran-
domised, placebo controlled, crossover methodology to
determine whether a low dose of ketamine potentiated
the antinociceptive effect of fentanyl without potentiating
the sedative effect of fentanyl. A battery of tests was assem-
bled to assess both nociception and sedation. Tests of
nociception used electrical current, pressure, and thermal
stimuli. Sedation was assessed by a subjective and objec-
tive score in addition to psychometric tests. Saline was
used as the control and propofol was used to validate the
tests of sedation. Cardiovascular and respiratory parame-
ters were also monitored in order to detect the occurrence
of adverse events.
This investigation was approved by the Southern Health
Human Research and Ethics Committee (Project number
96022A and 97074A) in accordance with the guidelines of
the National Health and Medical Research Council, Aus-
tralia (NHMRC). Ten healthy male volunteers were
recruited via bulletin board advertisements. The volun-
teers were trained in the test procedures employed and
medically screened. Volunteers were excluded if they had
a history of cardiac, neurological, or musculoskeletal dis-
ease. Other exclusion criteria included a history of drug
abuse, pain syndromes, myasthenia gravis, acute narrow
angle glaucoma, asthma, or heart failure, concurrent use
of any analgesics, sedatives, erythromycin, MAO inhibi-
tors, or allergy to propofol, fentanyl, or ketamine.
The ten volunteers each attended five three-hour labora-
tory sessions on separate occasions. In each session, the
volunteer received either one of the drug treatments or
saline (Table 1). Therefore, each volunteer was exposed to
each of the five treatments, over five sessions, with the
order of treatment randomised for each volunteer. During
each session, the test battery was performed prior to drug
administration as a measure of 'baseline' and then
repeated when each of the four targeted concentrations
were reached.
The orders of tests within the test battery were not varied.
The physiological measures were conducted first, fol-
lowed by the sedation tests, and lastly the nociception
tests. Before and after each test battery was performed, a
blood sample was taken to establish the drug serum con-
centration. The duration of each test battery was approxi-
mately 20–30 minutes, and between each battery the
volunteer was instructed to rest for approximately 20 min-
utes while the drug serum concentration was increased
according to the administration protocol.
The drugs were administered by serum target controlled
intravenous infusions (Stanpump; Shafer, CA. 94304,
USA, revision November 5, 1996; and a Harvard 22
syringe pump). This method was utilised to maintain a
stable serum concentration for the duration of the test bat-
tery. Two identical computer and syringe pump systems
using opaque intravenous tubing were employed and
operated in parallel at all times. The syringe pumps were
hidden from both the investigator and the volunteer
within an opaque sound-proofed box. Two intravenous
catheters (20–22 gauge) were inserted – one for the infu-
sion of the study drug and the other for the withdrawal of
blood for serum concentration assay.
Blood samples were transferred to a SST gel and clot acti-
vator vacutainer (Becton Dickinson, Franklin Lakes, NJ,
USA) and allowed to clot. Immediately after clotting, the
samples were centrifuged at 3500 rpm for 10 minutes. The
serum was then frozen in liquid nitrogen before being
stored in a refrigerator – fentanyl and ketamine samples
were stored at -4°C whereas propofol samples were refrig-
erated at -20°C. A scientist who was blinded to the serum
concentrations targeted conducted the analysis of theBMC Anesthesiology 2005, 5:2 http://www.biomedcentral.com/1471-2253/5/2
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serum samples. Propofol was analysed using a method
similar to Plummer [10]. Fentanyl and ketamine concen-
trations were analysed using a method based on that of
Bjorkman and Stanski. [11].
The pain threshold to electrical current was determined
using a computer controlled constant current stimulator
(Amlab International Pty Ltd, NSW 2113, Australia). A
train of five 1 ms unipolar rectangular pulses, at a fre-
quency of 200 Hz, lasting 25 ms was delivered using sin-
gle-use disposable Silver-silver chloride electrodes
(9013S0241, Medtronic Dantec, NSW, Australia) with a
contact area of 0.54 cm2 applied 2 cm apart to the medial
non-dominant wrist. The increasing and decreasing stair-
case method was used to determine the electrical pain
threshold, which was defined as the minimum amount of
current resulting in a stimulation that was graded as
"painful". The mean of three consecutive measurements
was used in subsequent analysis.
The pain threshold to contact heat was determined using
the ascending ramp method (Somedic Thermotest,
Somedic AB, Sweden; applied to the volunteer's non-
dominant wrist). A contact thermistor (Hewlett Packard
patient monitor M1165A, Model 54S Mass. 02254, USA)
was used to monitor the temperature of the volunteer's
skin (adjacent to the wrist on the non-dominant forearm)
during the session. The pain threshold to pressure was
measured using the ascending ramp method (Somedic
Algometer, Somedic, Sweden; applied to the non-domi-
nant middle-finger nail bed). Pressure was applied at the
increasing rate of 40 kPa/s over a contact surface area of 1
cm2. For both tests, the mean of five consecutive measure-
ments was used in subsequent analysis.
The volunteers were asked to rate the symptom of seda-
tion with a visual analogue score by placing a vertical
mark through a horizontal 100 mm line with a pencil. The
caption "I feel drowsy" was printed above the horizontal
line and the left and right ends of the line were labelled
with the statements, "not at all" and "extremely" respec-
tively. The investigator – who was unaware of the nature
of the drug treatment – assessed the volunteers level of
sedation using the Observer Assessment of Alertness/
Sedation Scale (OASS) [12]. These scores were measured
once during each test battery.
The Symbol Digit Modalities Test (SDMT) is a pen and
paper test in which nine symbols are paired with digits
and 110 blank squares associated with digits are required
to be filled in within 90 seconds [13]. Parallel forms were
used in random order. The number of errors that were
made during the SDMT test was recorded and an inciden-
tal recall task immediately following the primary test was
performed. For this, the volunteers were given a new sheet
composed of a line of 15 symbols in which all nine sym-
bols were included at least once. The volunteer was then
asked to fill in the number associated with the symbol.
Where a symbol appeared more than once, and the volun-
teer correctly identified the number on one occasion and
incorrectly on another occasion, credit for the correct
identification was given.
A simple auditory reaction time was measured by compu-
ter (Amlab International Pty Ltd, NSW 2113, Australia).
In this test, the volunteer pushed a micro-switch button in
response to a tone using a handset in the dominant hand.
The Finger Tapping test was included to assess the effect of
the study drugs on the motor nervous system. The volun-
teers were asked to tap a micro-switch contained within a
modified computer serial mouse (Microsoft Corporation,
USA) as rapidly as possible over ten seconds and the
number of taps were counted. For both of these tests the
mean of five consecutive measurements was used in the
subsequent analysis.
During each test battery a Hewlett Packard patient moni-
tor (M1165A, Model 54S, Mass. 02254, USA) was used to
measure the volunteers' blood pressure, pulse rate, and
pulse oximetry. In addition, a small-volume circuit
consisting of a mouthpiece, Wrights Respirometer, and an
in-line Capnometer sensor (Hewlett Packard, Model
Table 1: Drug Concentrations Targeted
Baseline Concentration 1 Concentration 2 Concentration 3 Concentration 4
P l a c e b o  ( s a l i n e ) -----
Propofol (µg/ml) 0.00 0.15 0.30 0.60 0.90
Ketamine (ng/ml) 0.00 15.00 30.00 60.00 120.00
Fentanyl (ng/ml) 0.00 0.20 0.40 0.80 1.20
Ketamine (ng/ml) & 0.00 30.00 30.00 30.00 30.00
Fentanyl (ng/ml) 0.00 0.20 0.40 0.80 1.20BMC Anesthesiology 2005, 5:2 http://www.biomedcentral.com/1471-2253/5/2
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14360A, Mass. 02254, USA) was used to determine the
respiratory rate, tidal volume (averaged from ten consecu-
tive breaths), and the end-tidal carbon dioxide. The
minute volume was calculated from the tidal volume and
the respiratory rate.
The results were analysed by repeated-measures analysis
of variance (ANOVA), incorporating the Greenhouse-
Geisser adjustment for multisample asphericity (com-
pound asymmetry). For each outcome variable the analy-
sis was conducted across the five treatments (placebo,
propofol, ketamine, fentanyl, and fentanyl and ketamine
combined), and over the five ascending doses. Within the
ANOVA, the hypothesis tested was that provided by the
within-subject interaction term Drug by Dose. The result of
testing this factor was that this method tested for parallel-
ism of the response curves across ascending doses according
to drug treatment. Thus, it identified differences between
the drugs with respect to the slope or profile of each dose
response curve. Because the above hypothesis was tested
for each of the 18 outcome measures subjected to
ANOVA, the familywise Type I error-rate was controlled
by the Ryan-Holm step-down Bonferroni procedure. A
value of P ≤ 0.05 was regarded as statistically significant.
Further analysis and illustration was confined to those
dose response curves that were significantly different
between the study drugs. When a significant difference
between the dose response curves was determined, the
dose response curves were ranked according to similarity
in order to establish the origin of the significant differ-
ence. This was achieved by a stepwise addition of each
dose response curve until a significant difference was
detected by ANOVA testing.
The OAAS scores were analysed by Friedman's test
because of the lack of variance of the OAAS scores at base-
line. The profile of the response curve of each volunteer to
the increasing drug concentrations was summarised by
the sum of the OAAS scores across the five concentrations
of each drug. The summary of each drug profile was then
blocked by the term volunteer. Where a significant differ-
ence between the drug profiles was detected, the profiles
were classified according to similarity in order to establish
the origin of the significant difference. This was achieved
by a stepwise addition of profile data with similar appear-
ances until a significant difference was detected by the
Friedman test in a similar manner as previously described
with ANOVA. Statistical calculations were conducted
using Minitab (Release 13.31) for the Friedman Test and
SPSS for Windows (Release 10.0.7) for all other
procedures.
Results
Ten volunteers completed all of the experiments and none
were excluded or withdrawn. The mean age, weight, and
height (standard deviation) of the group were 23 (4.2)
years, 66.3 (4.6) kg, and 173.5 (33.5) cm. The study drugs
had a dose-dependent effect on the electrical current and
pressure pain, SDMT, subjective sedation VAS and OASS,
reaction time, and finger-tapping tests (Table 2 and Table
3). The remaining tests did not demonstrate a difference
between the study drugs and placebo.
All drugs resulted in a dose dependent increase in the elec-
trical pain threshold compared with placebo (Figure 1).
The dose response curve of fentanyl combined with keta-
mine was markedly steeper than the dose response curves
of fentanyl alone (P < 0.05; ANOVA). While a ketamine
serum concentration of 30 ng/ml did not result in a
change in electrical pain threshold when administered
alone (P = 0.32; two-way ANOVA), when it was added to
a fentanyl serum concentration of 0.4 ng/ml the combina-
tion resulted in greater increase in pain threshold than
that of fentanyl administered alone (P < 0.01; two-way
ANOVA).
Table 2: Differences between the Profiles of the Study Drug 
Dose Response Curves
Outcome Variable P value
Nociception Tests
Electrical pain threshold <0.01 *
Pressure pain threshold <0.01 *
Heat pain threshold 0.99
Skin temperature 0.59
Sedation Score
Subjective sedation visual analogue score 0.01 *
OASS <0.01 *
Psychometric Tests
SDMT 0.03 *
SDMT errors 0.17
SDMT recall 0.99
Reaction time <0.01 *
Finger tapping test <0.01 *
Physiological Tests
Systolic blood pressure 0.34
Diastolic blood pressure 0.99
Heart rate 0.99
Respiratory rate 0.99
Tidal volume 0.73
Pulse oximetry 0.99
End tidal carbon dioxide 0.99
Minute volume 0.99
SDMT denotes symbol digit modalities test; OASS, observer 
assessment of alertness/sedation scale; *, P ≤ 0.05BMC Anesthesiology 2005, 5:2 http://www.biomedcentral.com/1471-2253/5/2
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Fentanyl, both alone and in combination with ketamine,
produced a dose dependent increase in pressure pain
threshold compared with saline, whereas ketamine alone
was ineffective at all doses (Figure 2). The dose response
profiles of fentanyl alone and in combination with keta-
mine were not different (P = 0.35; ANOVA). No difference
Table 3: Origins of the Significant Differences between the Study Drugs with Respect to the Profile of the Dose Response Curves (P ≤ 
0.05)
Outcome Variable Origins of Difference in Profile by Drug
Nociception Tests
Electrical pain threshold fentanyl & ketamine versus ketamine, fentanyl versus saline
Pressure pain threshold fentanyl & ketamine, fentanyl, versus ketamine, saline
Sedation Score
Sedation visual analogue ketamine, fentanyl, propofol, fentanyl & ketamine versus saline
OASS propofol versus ketamine, fentanyl, fentanyl & ketamine, versus saline
Psychometric Tests
SDMT propofol versus ketamine, fentanyl, fentanyl & ketamine versus saline
Reaction time propofol versus ketamine, fentanyl, fentanyl & ketamine, saline
Finger tapping test propofol versus ketamine, fentanyl, fentanyl & ketamine, saline
SDMT denotes symbol digit modalities test; OASS, observer assessment of alertness/sedation scale.
The Antinociceptive Effect Measured using ECT Figure 1
The Antinociceptive Effect Measured using ECT. The electri-
cal pain threshold is expressed as the mean electrical pain 
threshold of all volunteers (n = 10) when a steady serum 
concentration of the treatment drug had been achieved. 
These values are standardised by the threshold value at base-
line in order to illustrate the difference in profiles between 
each treatment arm. The serum concentrations targeted are 
listed in Table 1 and enumerated on the abscissa using a loga-
rithmic scale.
The Antinociceptive Effect Measured using Pressure  Algometry Figure 2
The Antinociceptive Effect Measured using Pressure Algom-
etry. The pressure pain threshold was expressed as the mean 
pressure pain threshold of all volunteers (n = 10) when a 
steady plasma level of the treatment drug had been achieved. 
These values were then standardised by the threshold value 
at baseline in order to illustrate the difference in profiles 
between each treatment arm. The serum concentrations tar-
geted are listed in Table 1 and enumerated on the abscissa 
using a logarithmic scale.BMC Anesthesiology 2005, 5:2 http://www.biomedcentral.com/1471-2253/5/2
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was seen between the study drugs (including placebo)
when assessed with heat (Figure 3).
All of the study drugs were associated with increased seda-
tion compared with placebo (Table 1) when assessed by
the objective psychometric tests (Figure 4, 5, and 6) and
the scores of sedation (Figure 7 and 8). Propofol was asso-
ciated with a more marked subjective sedative effect than
either fentanyl or ketamine – alone or in combination
(Figure 7Error! Reference source not found.). There was
no difference between the sedative effect of fentanyl and
fentanyl in combination with ketamine as assessed by the
subjective sedation VAS, OASS, and SDMT (Figure 4Error!
Reference source not found.). Specifically, fentanyl 0.4
ng/ml combined with ketamine 30 ng/ml was not associ-
ated with increased sedation in comparison with fentanyl
0.4 ng/ml alone. While Propofol was associated with a
reduced number of finger taps and an increase in reaction
time compared with placebo, none of the other study
drugs had any significant effect on these measures of
sedation.
The serum concentrations remained steady at each con-
centration targeted and the ketamine serum concentration
remained steady throughout the duration of the
experiment when it was combined with fentanyl in a fixed
dose (Table 4).
Discussion
Pre-clinical investigation of the antinociceptive effect of
ketamine and morphine by Chapman and Dickenson [8]
led Schmid, Sandler and Katz [14] to hypothesize that
there may be a dose of ketamine that has no analgesic
potency on its own, but when used in combination with
an opioid might produce superior pain relief than either
drug alone. To test this hypothesis, the present study
constructed a dose response curve for ketamine, from
which a dose of ketamine that had no antinociceptive
effect was identified (30 ng/ml). When this dose of keta-
mine was combined with fentanyl the resulting antinoci-
ception, as assessed by electrical current pain threshold,
was greater than that of either drug alone and clear poten-
tiation was demonstrated. In addition, while ketamine
potentiated the antinociceptive effect of fentanyl, the sed-
ative effect was not increased. Therefore, the data pre-
sented here supports the hypothesis put forward by
Schmid et al [14].
The Antinociceptive Effect Measured using Heat Figure 3
The Antinociceptive Effect Measured using Heat. The heat 
pain threshold was expressed as the mean heat pain thresh-
old of all volunteers (n = 10) when a steady plasma level of 
the treatment drug had been achieved. These values were 
then standardised by the threshold value at baseline in order 
to illustrate the difference in profiles between each treat-
ment arm. The serum concentrations targeted are listed in 
Table 1 and enumerated on the abscissa using a logarithmic 
scale.
The Psychometric Effect Measured by SDMT The SDMT Figure 4
The Psychometric Effect Measured by SDMT The SDMT. 
score was expressed as the mean score of all volunteers (n = 
10) when a steady serum concentration of the treatment 
drug had been achieved. These values are standardised by the 
threshold value at baseline in order to illustrate the differ-
ence in profiles between each treatment arm. The serum 
concentrations targeted are listed in Table 1 and enumerated 
on the abscissa using a logarithmic scale.BMC Anesthesiology 2005, 5:2 http://www.biomedcentral.com/1471-2253/5/2
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A review of the recent preclinical work investigating the
interaction between opioid agonists and NMDA antago-
nists shows mixed results. Some authors have
demonstrated that NMDA antagonists enhance the anti-
nociceptive effect of opioids [15,16]. whereas others have
been unable to confirm these findings [17,18].
Some authors such as Redwine et al [19] have gone so far
as to suggest that NMDA receptors are not involved in
acute opiate mediated analgesia. In order to resolve these
difficulties, a number of investigators have suggested that
factors other than receptor interactions may have resulted
in the heterogeneous results seen. These factors may
include; the opioid agonist and the NMDA antagonist
chosen for investigation [19-23], the nociceptive test cho-
sen [16], and the species used for investigation [24].
The findings of this current investigation support the
hypothesis that the nociceptive test used is an important
determinant of the outcome of investigations assessing
the interaction between ketamine and fentanyl, that is, the
interaction between ketamine and fentanyl is stimulus
dependent. Despite fentanyl-mediated analgesia being
clearly potentiated by ketamine when assessed by ECT,
this was not seen when it was assessed by pressure algom-
etry. The inability of pressure to demonstrate potentiation
was consistent with other investigators who have found
that the antinociceptive activity of ketamine on pressure
nociception is dependent on preconditioning, such as
preconditioning which produces neuropathic pain [25].
Clearly such preconditioning was absent in the current
study.
This study encountered similar difficulties to that of
Sethna  et al who found that a large variation in the
assessment of C-fibre mediated pain made capsaicin –
and in our case heat – a difficult modality to use in the
study of nociception [26]. The global failure of all of the
drug infusions to increase the heat pain thresholds
suggests that either the assessment of heat pain threshold
was inadequate or the drug doses used were too low. The
heat pain thresholds were assessed by the ascending ramp
method with a continuous stimulus, which increased
intensity at a constant rate. This method was more
susceptible to provoking conditioned timed responses in
the volunteers compared with the discrete stimuli used for
the assessment of electrical current pain thresholds. Other
Psychometric Effect Measured by Reaction Time Figure 5
Psychometric Effect Measured by Reaction Time. The reac-
tion time was expressed as the mean of all volunteers (n = 
10) when a steady serum concentration of the treatment 
drug had been achieved. These values are standardised by the 
threshold value at baseline in order to illustrate the differ-
ence in profiles between each treatment arm. The serum 
concentrations targeted are listed in Table 1 and enumerated 
on the abscissa using a logarithmic scale.
Psychometric Effect Measured by the Finger Tapping Test Figure 6
Psychometric Effect Measured by the Finger Tapping Test. 
The number of finger taps was expressed as the mean of all 
volunteers (n = 10) when a steady serum concentration of 
the treatment drug had been achieved. These values are 
standardised by the threshold value at baseline in order to 
illustrate the difference in profiles between each treatment 
arm. The serum concentrations targeted are listed in Table 1 
and enumerated on the abscissa using a logarithmic scale.BMC Anesthesiology 2005, 5:2 http://www.biomedcentral.com/1471-2253/5/2
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factors that weakened the assessment of heat pain thresh-
olds included the mechanical stimulation caused by con-
tact of the thermode, which may produce Aβ-fibre
mediated interference of the C-fibre sensory input. The
authors hypothesize that the use of discrete heat stimuli –
such as that produced by laser [27] – may have improved
heat stimulation's ability to demonstrate the nature of the
interaction between fentanyl and ketamine using this
paradigm.
Clinical studies assessing the interaction of ketamine and
opioids have also produced mixed results however,
consistent with the findings of the current study, a review
of the interaction between ketamine and opioids in allevi-
ating clinical pain has demonstrated that ketamine
enhances opioid-mediated analgesia [28]. Schmid et al in
their review of the clinical use of ketamine for the man-
agement of postoperative pain differentiated between a
high and a low dose range of ketamine [14]. Both the
sedative and the psychotomimetic effects of ketamine are
known to be dose dependent [29]. As opposed to idiosyn-
cratic drug effects, the dose responsive nature of the
unwanted sedative and psychotomimetic effects of
ketamine provided the opportunity that a low dose of
ketamine could be used to provide analgesia without their
occurrence. However, due to the large overlap in the
respective ketamine dose response curves for analgesia
and sedation, separation of these effects was difficult
when ketamine was used alone. Clinical studies using ket-
amine alone for analgesia have often reported adequate
analgesia with associated psychotomimetic effects, or
have reported an acceptable level of adverse effects but
poor analgesia [30-33].
The primary advantage of combinational therapy relies on
the improvement of the desired effect without a
concomitant increase in its adverse effects, which some
authors have seen as a requirement for the demonstration
of a synergistic interaction [26]. That is, it is considered
that a synergistic interaction exists between two drugs
when the effect of a combination is greater than the sum
of the effects produced by each drug given alone. How-
ever, it is clear that whilst an increase of the desired effects
is desirable, what is critical for clinical advantage is that
the occurrence of adverse effects is not increased in a sim-
ilar manner. Some authors consider that an increase in the
beneficial effects of a combination without an increase in
Subjective Sedation Measured by Visual Analogue Score Figure 7
Subjective Sedation Measured by Visual Analogue Score. This 
figure shows the effect of the five treatments on the visual 
analogue score (VAS) given to the statement, "I feel drowsy". 
The VAS was expressed as the mean score of all volunteers 
(n = 10) when a steady serum concentration of the treat-
ment drug had been achieved. All drug treatments were 
associated an increase in VAS compared to saline. The serum 
concentrations targeted are listed in Table 1 and enumerated 
on the abscissa using a logarithmic scale.
Sedation Measured by OASS Figure 8
Sedation Measured by OASS. The OASS was expressed as 
the median score of all volunteers (n = 10) when a steady 
serum concentration of the treatment drug had been 
achieved. The serum concentrations targeted are listed in 
Table 1 and enumerated on the abscissa using a logarithmic 
scale.BMC Anesthesiology 2005, 5:2 http://www.biomedcentral.com/1471-2253/5/2
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the adverse effects is more important than the existence of
synergy per se [34].
Human dose ranging studies of ketamine are scarce and
consequently the doses and methods of administration of
ketamine in clinical studies are numerous. Schmid et al
proposed that dose ranging studies were required as part
of a research program to explore the clinical usefulness of
ketamine as an adjunct to opioid analgesia in 1999 [14].
In this study, the highest serum concentrations of keta-
mine targeted were related to regimens that have been
used for analgesia clinically [35-37]. While the human
laboratory paradigm is one step removed from the clinical
arena, it is well suited to dose ranging studies that are vital
for the rational planning of clinical investigations.
Clinical and human laboratory studies investigating keta-
mine for the management of postoperative pain are heter-
ogenous in design and varied in their appraisal of the
effect of ketamine in conjunction with opioids for the
management of pain [38-52]. In these trials ketamine has
been given by the epidural, intramuscular, and intrave-
nous routes, in addition to the description of intrathecal
use [53-59]. Javery et al described reduced pain ratings
and morphine consumption following microdiscectomy
when patients received a combination of ketamine and
morphine rather than morphine alone [44]. By contrast
most studies have investigated pain following abdominal
surgery and the results have been less encouraging
[45,46]. While these studies may yet lead to the
conclusion that the surgical procedure conducted is
important in determining whether ketamine augments
postoperative opioid analgesia or not; other factors such
as the dosing regimen also varies across these studies and
appears to be a dominant reason for such variable results.
Studies that have combined ketamine with morphine in
an intravenous Patient Controlled Analgesia (PCA) pump
have usually failed to demonstrate a reduction in mor-
phine consumption [45-48]. This may reflect the
mismatch of ketamine's and morphine's respective time
response curves for analgesia. Compared with morphine,
ketamine is a short acting drug. Ketamine's short duration
of action was demonstrated when it reduced ischaemic
arm pain for less than 5 and 10 minutes respectively when
used intravenously in doses of 125 µg/kg and 250 µg/kg
[2]. Therefore, if the use of the PCA pump is predomi-
nantly determined by the longer acting morphine, the
combination of ketamine and morphine may result in
troughs of ketamine's serum concentration, and occa-
sional peaks when the PCA pump is triggered. This is
consistent with the finding that ketamine co-administered
with morphine in PCA pumps did not improve patients'
VAS in six studies overall when assessed by weighted
mean difference [28]. Therefore, because ketamine has a
small therapeutic window within which analgesia is not
accompanied by adverse effects, great importance should
be placed on the dosing regimen chosen.
Some studies have used steady intravenous infusions of
ketamine in addition to PCA pump morphine to relieve
abdominal postoperative-pain. Both manual infusions
and computer controlled serum targeted infusions of ket-
amine have been studied [38-41,49-52]. However, while
Table 4: Measured Serum Drug Concentrations
Baseline Concentration 1 Concentration 2 Concentration 3 Concentration 4
Mean SD Mean SD Mean SD Mean SD Mean SD
Propofol (µg/ml) 0.00 (0.00) 0.10 (0.04) 0.26 (0.07) 0.58 (0.18) 0.92 (0.24)
0.11 (0.03) 0.31 (0.11) 0.62 (0.16) 0.91 (0.25)
Ketamine (ng/ml) 0.00 (0.00) 11.49 (4.31) 24.64 (6.68) 47.87 (18.03) 85.75 (31.87)
12.61 (4.85) 27.48 (11.62) 51.86 (21.54) 93.88 (38.26)
Fentanyl (ng/ml) 0.00 (0.00) 0.28 (0.03) 0.53 (0.09) 1.01 (0.15) 1.48 (0.26)
0.31 (0.07) 0.55 (0.13) 1.02 (0.21) 1.53 (0.25)
Ketamine (ng/ml) 0.00 (0.00) 25.59 (13.26) 30.29 (13.94) 30.73 (16.98) 29.88 (12.84)
25.41 (5.76) 35.41 (15.90) 29.82 (12.26) 31.58 (14.23)
&
Fentanyl (ng/ml) 0.00 (0.00) 0.27 (0.11) 0.49 (0.13) 1.05 (0.17) 1.57 (0.26)
0.29 (0.06) 0.57 (0.15) 1.09 (0.24) 1.57 (0.29)
SD denotes standard deviation. The upper and lower data in each cell represents the serum concentration measured at the beginning and at the end 
of each test battery respectively.BMC Anesthesiology 2005, 5:2 http://www.biomedcentral.com/1471-2253/5/2
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it may be expected that a steady manual infusion should
result in a stable serum concentration of ketamine, this
has not always been shown to be the case. Owen et al stud-
ied a regimen of ketamine consisting of a bolus and an
infusion which lasted 24 hours [39]. The subsequent anal-
ysis of the serum concentrations showed that a constant
serum concentration was achieved in fewer than half of
the thirty patients studied and that in the majority of
patients the serum concentrations rose continuously.
Therefore, while the published literature describing the
use of ketamine suggests that the dose of ketamine needs
to be carefully controlled, a manual infusion may not
always achieve the level of stability required. As dosage is
important in avoiding ketamine's side effects and ensur-
ing adequate NMDA receptor antagonism, the potentia-
tion of analgesia resulting from the combination of
ketamine with fentanyl that was found in this study is
likely to require a similar attention to dosing. In keeping
with this suggestion, Adriaenssens et al have shown
improved pain ratings and decreased morphine consump-
tion following laparotomy by targeting a ketamine serum
concentration of 100 ng/ml using the same pharmacoki-
netic software used in this study [38]. This present study
suggests that ketamine may provide enhanced opioid
analgesia at a third of this dose without adverse effects.
Notwithstanding this, in contrast to ketamine adminis-
tered in PCA pumps, ketamine co-administered with
morphine infusions have been shown to improve
patients' VAS in seven studies overall when assessed by
weighted mean difference [28].
An advantage of human laboratory investigation is the
ability to use greater number of drug doses and
combinations than is usually practical in clinical investi-
gations. There are few barriers to applying the knowledge
gained from this study to present day clinical medicine.
Doses and serum concentrations of ketamine have been
identified using a freely available pharmacokinetic pro-
gram and using the racemic form of ketamine, which is
licensed for clinical use internationally. The findings of
this study and those from published clinical studies sug-
gest that accurate and consistent administration of low
doses of ketamine are required in order to enhance the
antinociceptive effect of opioids and avoid adverse effects.
Conclusion
The effect of intravenous ketamine and fentanyl was stud-
ied in human volunteers using nociceptive and sedative
tests. A serum concentration of ketamine that did not alter
indices of sedation potentiated the antinociceptive effect
of fentanyl. This potentiation of antinociception occurred
without an increase in sedation suggesting that low doses
of ketamine might be combined with µ opioid agonists to
improve their analgesic effect in a clinical setting.
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